HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use TICOVAC safely and effectively. See full prescribing information for TICOVAC.
TICOVAC (Tick-Borne Encephalitis Vaccine), Suspension for intramuscular injection
Initial U.S. Approval: 2021
INDICATIONS AND USAGE
TICOVAC is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE). TICOVAC is approved for use in individuals 1 year of age and older. (1)
DOSAGE AND ADMINISTRATION
For intramuscular use only.
Primary Vaccination: Three doses (2.1)
A booster dose (fourth dose) may be given at least 3 years after completion of the primary immunization series if ongoing exposure or re-exposure to tick-borne encephalitis virus (TBEV) is expected.
DOSAGE FORMS AND STRENGTHS
Suspension for injection supplied as a 0.25 mL or 0.5 mL single-dose in pre-filled syringes. (3)
The most common adverse reactions are as follows:
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or VAERS at 1-800-822-7967 or http://vaers.hhs.gov.
See 17 for PATIENT COUNSELING INFORMATION.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.